Related Experiment Videos
An open dose finding study of melperone in treatment of agitation and irritability associated with dementia
Abstract:
Seventeen older patients with a diagnosis of Organic Brain Syndrome were placed on a four-week trial of melperone for treatment of behavioural disturbances associated with dementia. Efficacy evaluation of the drug revealed improved ratings of the patients in the areas of agitation/irritability, anxiety, unsociability, and mental alertness. Thirteen of the fourteen patients who completed the trial were rated generally as showing at least minimal improvement while on the drug. There were no serious side effects noted, with drowsiness the most frequent finding. These favourable results are suggestive of the usefulness of this drug, and point to the need for double-blind, comparative studies.
Insights
Melperone showed promise in treating behavioral disturbances in older patients with Organic Brain Syndrome, improving agitation and alertness. Minimal side effects were observed, suggesting further study is warranted.
Area of Science:
- Geriatric Psychiatry
- Pharmacology
- Neurology
Background:
- Dementia often presents with behavioral disturbances.
- Organic Brain Syndrome (OBS) impacts cognitive and behavioral functions in older adults.
- Effective and safe treatments for OBS-related behavioral issues are needed.
Purpose of the Study:
- To evaluate the efficacy of melperone in treating behavioral disturbances associated with dementia in older patients.
- To assess the safety and tolerability of melperone in this population.
Main Methods:
- A four-week open-label trial involving seventeen older patients diagnosed with Organic Brain Syndrome.
- Patients received melperone for behavioral disturbances.
- Efficacy and side effects were monitored.
Main Results:
- Significant improvements were observed in agitation/irritability, anxiety, unsociability, and mental alertness.
- Thirteen of fourteen completers showed at least minimal improvement.
- Drowsiness was the most common side effect; no serious adverse events were reported.
Conclusions:
- Melperone demonstrates potential as a treatment for behavioral disturbances in dementia associated with OBS.
- Favorable results suggest the need for larger, double-blind, comparative studies to confirm efficacy and safety.